Cerebrospinal and peripheral human immunodeficiency virus type 1 load in a multisite, randomized, double-blind, placebo-controlled trial of d-Ala₁-peptide T-amide for HIV-1-associated cognitive-motor impairment

Karl Goodkin Department of Psychiatry and Behavioral Sciences, University of Miami School of Medicine, Miami, Florida, USA; Department of Neurology, University of Miami School of Medicine, Miami, Florida, USA

Benedetto Vitiello Child and Adolescent Treatment and Preventive Intervention Research Branch, National Institute of Mental Health, Bethesda, Maryland, USA

William D Lyman Children's Research Center of Michigan, Children's Hospital of Michigan, Detroit, Michigan, USA; Department of Pediatrics, Wayne State University, Detroit, Michigan, USA

Deshratn Asthana Department of Psychiatry and Behavioral Sciences, University of Miami School of Medicine, Miami, Florida, USA

J Hampton Atkinson Department of Psychiatry, HIV Neurobehavioral Research Center, University of California at San Diego, San Diego, California, USA

Peter NR Heseltine Infectious Diseases Division, Quest Diagnostics Nichols Institute, San Juan Capistrano, California, USA

Rebeca Molina Department of Psychiatry and Behavioral Sciences, University of Miami School of Medicine, Miami, Florida, USA

Wenli Zheng Department of Psychiatry and Behavioral Sciences, University of Miami School of Medicine, Miami, Florida, USA

Imad Khamis Department of Psychiatry and Behavioral Sciences, University of Miami School of Medicine, Miami, Florida, USA

Frances L Wilkie Department of Psychiatry and Behavioral Sciences, University of Miami School of Medicine, Miami, Florida, USA

Paul Shapshak Department of Psychiatry and Behavioral Sciences, University of Miami School of Medicine, Miami, Florida, USA; Department of Pathology, University of Miami School of Medicine, Miami, Florida, USA

show all

Citations (1)

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Jetske M Emmelkamp & Jürgen K Rockstroh. (2008) Maraviroc, risks and benefits: a review of the clinical literature. Expert Opinion on Drug Safety 7:5, pages 559-569.
Read now

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Cerebrospinal and peripheral human immunodeficiency virus type 1 load in a multisite, randomized, double-blind, placebo-controlled trial of d-Ala₁-peptide T-amide for HIV-1-associated cognitive-motor impairment

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Cerebrospinal and peripheral human immunodeficiency virus type 1 load in a multisite, randomized, double-blind, placebo-controlled trial of d-Ala1-peptide T-amide for HIV-1-associated cognitive-motor impairment

Citations (1)

Read on this site (1)

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Cerebrospinal and peripheral human immunodeficiency virus type 1 load in a multisite, randomized, double-blind, placebo-controlled trial of d-Ala₁-peptide T-amide for HIV-1-associated cognitive-motor impairment